ATE297755T1 - Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind - Google Patents

Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind

Info

Publication number
ATE297755T1
ATE297755T1 AT98915471T AT98915471T ATE297755T1 AT E297755 T1 ATE297755 T1 AT E297755T1 AT 98915471 T AT98915471 T AT 98915471T AT 98915471 T AT98915471 T AT 98915471T AT E297755 T1 ATE297755 T1 AT E297755T1
Authority
AT
Austria
Prior art keywords
lactoferrin
allergens
treatment
conditions caused
asthma
Prior art date
Application number
AT98915471T
Other languages
English (en)
Inventor
Ian Kimber
Marie Cumberbatch
Rebecca J Dearman
Orla M Conneely
Pauline Ward
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Application granted granted Critical
Publication of ATE297755T1 publication Critical patent/ATE297755T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98915471T 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind ATE297755T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4189097P 1997-04-10 1997-04-10
PCT/US1998/007234 WO1998044940A1 (en) 1997-04-10 1998-04-10 Use of lactoferin in the treatment of allergen induced disorders

Publications (1)

Publication Number Publication Date
ATE297755T1 true ATE297755T1 (de) 2005-07-15

Family

ID=21918897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915471T ATE297755T1 (de) 1997-04-10 1998-04-10 Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind

Country Status (12)

Country Link
US (1) US20030190303A1 (de)
EP (1) EP0979099B1 (de)
JP (1) JP2001519815A (de)
CN (1) CN1262625A (de)
AT (1) ATE297755T1 (de)
AU (1) AU747385C (de)
CA (1) CA2285960A1 (de)
DE (1) DE69830582T2 (de)
ES (1) ES2245028T3 (de)
IL (1) IL132293A0 (de)
NZ (1) NZ500712A (de)
WO (1) WO1998044940A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050076A1 (en) * 1997-05-03 1998-11-12 Board Of Regents, The University Of Texas System Methods for preventing and treating the insult-induced metabolic imbalance in humans and other animals
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP4787445B2 (ja) * 2000-01-14 2011-10-05 株式会社明治 抗原特異的ＩｇＥ抗体産生抑制剤
RU2165769C1 (ru) * 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
EP3492100B1 (de) 2001-06-26 2021-12-08 Amgen Inc. Antikörper gegen opgl
WO2003057245A1 (fr) * 2001-12-28 2003-07-17 Nrl Pharma, Inc. Compositions servant a ameliorer le metabolisme lipidique
EP1477182A4 (de) 2002-01-21 2009-05-27 Nrl Pharma Inc Neue analgetika
CN100467060C (zh) * 2002-05-10 2009-03-11 阿根尼克斯有限公司 通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途
US7238661B2 (en) 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
CA2497884C (en) 2002-09-06 2013-10-22 Brian Varnum Therapeutic human anti-il-1r1 monoclonal antibody
SI1545587T1 (sl) * 2002-09-16 2011-06-30 Agennix Inc Sestavki laktoferina in postopki za zdravljenje diabetiäśne razjede
WO2004052281A2 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
AU2003296447A1 (en) 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
JP2007524654A (ja) * 2003-06-06 2007-08-30 エイジェニックス インコーポレイテッド 癌ワクチン中のアジュバントとしてのラクトフェリン
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
WO2005121329A2 (en) * 2004-06-11 2005-12-22 Syngenta Limited Method for ameliorating an inflammatory skin condition
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
AU2006223754B2 (en) * 2005-03-15 2008-11-06 Campina Nederland Holding B.V. Dermatologic use of milk proteins
US8178486B2 (en) * 2005-07-21 2012-05-15 Animal Technology Institute Taiwan Method for promoting hair growth
EP1937298A4 (de) * 2005-10-14 2009-11-11 Auckland Uniservices Ltd Verwendung von lactoferrin-fragmenten und hydrolysaten
EP1952818A4 (de) * 2005-10-27 2009-10-21 Sunstar Inc Hemmer der osteoklastenbildung, zusammensetzung zur oralen verabreichung und prophylaktisches oder therapeutisches mittel gegen knochenkrankheiten mit lactoferrin-haltigem liposom
AU2011242415B2 (en) * 2010-04-23 2017-02-16 Probiotec Limited Eczema treatment
CN102370964B (zh) * 2010-08-16 2015-12-09 李兴德 白细胞介素受体拮抗蛋白在制备皮肤外用制剂中的应用
IT201800002457A1 (it) * 2018-02-07 2019-08-07 Neilos S R L Composizione per la prevenzione e il trattamento delle affezioni delle vie respiratorie
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2021116403A1 (en) * 2019-12-11 2021-06-17 N.V. Nutricia Nutritional composition for improving immune fitness
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596986B1 (fr) * 1986-04-11 1988-09-23 Sederma Sa Utilisation de la lactoferrine dans des preparations cosmetiques, antiradicaux libres
FR2641696B2 (fr) * 1986-04-11 1991-03-08 Sederma Sa Utilisation d'un melange renfermant de la lactoferrine dans des preparations cosmetiques anti-radicaux libres
FR2685202B1 (fr) * 1991-12-24 1995-03-24 Sederma Sa Nouvelle methode de traitement pharmaceutique et cosmetique pour la regulation de la seborrhee, de l'acne et de la flore cutanee.
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
JPH05279266A (ja) * 1992-04-02 1993-10-26 Imuno Japan:Kk 歯周病の治療・予防用医薬組成物
JP3163171B2 (ja) * 1992-07-15 2001-05-08 森永乳業株式会社 ＩｇＡ産生促進剤
JP3746081B2 (ja) * 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
JPH0859450A (ja) * 1994-08-18 1996-03-05 Kose Corp 皮膚外用剤
JP2832517B2 (ja) * 1994-12-09 1998-12-09 雪印乳業株式会社 大腸菌付着阻止剤
JP3911642B2 (ja) * 1995-06-06 2007-05-09 株式会社加美乃素本舗 皮膚外用剤
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof

Also Published As

Publication number Publication date
DE69830582D1 (de) 2005-07-21
IL132293A0 (en) 2001-03-19
AU747385C (en) 2003-01-30
DE69830582T2 (de) 2006-05-04
US20030190303A1 (en) 2003-10-09
CA2285960A1 (en) 1998-10-15
NZ500712A (en) 2002-10-25
CN1262625A (zh) 2000-08-09
EP0979099A1 (de) 2000-02-16
EP0979099B1 (de) 2005-06-15
WO1998044940A1 (en) 1998-10-15
AU747385B2 (en) 2002-05-16
JP2001519815A (ja) 2001-10-23
AU6964798A (en) 1998-10-30
ES2245028T3 (es) 2005-12-16

Similar Documents

Publication Publication Date Title
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
ATE296799T1 (de) P38-inhibitoren
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
FI935585A0 (fi) Pyrrolopyrimidiner
BR0007556A (pt) Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
MY132496A (en) Inhibitors of p38
MY117696A (en) INHIBITORS OF p38
DE69729796D1 (de) Verwendung von synergistischen zusammensetzungen von il-12 und ifn-alpha für die behandlung von infektiösen krankheiten
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
DE69030212T2 (de) Verwendung von Derivaten des 4-Phenyl-1,2,3,4-tetrahydro-1-naphthalenamins zur Behandlung von Psychose, Entzündung und als Immununterdrücker
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE60238149D1 (de) Arylsulfonamid-Derivate zur Verwendung als CCR3-Antagonisten bei der Behandlung von inflammatorischen und immunologischen Erkrankungen
NO971902D0 (no) Bindingsmidler til CD23
DE69623271T2 (de) Verwendung von imidazo-(1,2-a)-pyridin-3-acetamid-derivaten für die therapeutische behandlung von neuropsychiatrischen syndromen in zusammenhang mit störungen der nervenbahnen der basalganglien
ATE138567T1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
DE69524093T2 (de) Kombination von prokoagulans und cytokin oder induktor seiner produktion für die behandlung von tumoren
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
EE200100125A (et) TAN-1057 derivaadid
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
DE69613567D1 (de) Benzamide für behandlung von neurodegenerativen störungen
DE60230044D1 (de) Isochinolin-inhibitoren von p38
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties